Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-4-secreting Lactobacillus paracasei
- Development stage
- Preclinical
- Lead developer
- The First People's Hospital of Yunnan Province
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
IL-4-secreting Lactobacillus paracasei is an engineered live biotherapeutic product (LBP) designed for the treatment of acute lung injury (ALI). Utilizing synthetic biology, the probiotic strain Lactobacillus paracasei is engineered to locally deliver the anti-inflammatory cytokine interleukin-4 (IL-4). The therapeutic is further enhanced with a material-based surface modification that enables targeted accumulation in inflamed lung tissue and provides reactive oxygen species (ROS) scavenging capacity. In preclinical models of ALI induced by LPS and Pseudomonas aeruginosa, this dual-functional engineered probiotic has demonstrated the ability to suppress pro-inflammatory cytokines (TNF-α and IL-6), reduce intracellular ROS levels, and improve pulmonary histopathology. Additionally, metabolomic profiling indicates that the treatment remodels the pulmonary microenvironment by increasing host-beneficial metabolites such as indole-3-butyric acid.
- Other names
- engineered Lactobacillus paracaseiIL-4-secreting probioticsIL4-secreting probioticsIL 4-secreting probiotics
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on IL-4-secreting Lactobacillus paracasei.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-4-secreting Lactobacillus paracasei.